• Company
    • Company Overview
    • Team
    • Board
  • Approach
    • Approach
    • Opioid Induced Respiratory Depression
    • Paediatric
    • CHRONIC OBSTRUCTIVE PULMONARY DISEASE
  • News
  • Careers
  • Contact
PneumoWave PneumoWave
  • Company
    • Company Overview
    • Team
    • Board
  • Approach
    • Approach
    • Opioid Induced Respiratory Depression
    • Paediatric
    • CHRONIC OBSTRUCTIVE PULMONARY DISEASE
  • News
  • Careers
  • Contact
PneumoWave

Altair Medical accelerates development schedule by adopting FDA cleared cloud data management platform

Home / News / Press Release / Altair Medical accelerates development schedule by adopting FDA cleared cloud data management platform
inPress Release

Altair Medical accelerates development schedule by adopting FDA cleared cloud data management platform

Wednesday 20th October

Altair Medical, (“Altair”) aims to revolutionize care for respiratory symptoms and diseases with its advanced, remote respiratory monitoring platform. The company, which was awarded FDA Breakthrough Medical Device designation earlier this year, today announced that it had chosen to transition to Galen Data’s cloud platform to accelerate commercial development of its platform.

Dr. Bruce Henderson, a Forensic Physician, founded Altair Medical after recognizing the advantages that comprehensive remote respiratory monitoring would have for patients with respiratory illnesses such as Asthma, COPD, Respiratory Infection and OIRD.

Outside of hospitals, many respiratory monitors rely on photoplethysmography (PPG) sensors, which use cardiac data to calculate breathing rates. This method can be inaccurate and difficult to determine anything besides breathing rates.

Altair’s technology combines hardware and software to capture the patients’ breathing data, in a clinical environment or remotely. With real-time respiratory metrics generated from a range of proprietary algorithms, Altair aims to provide physicians significantly more information about patients’ health.
Real-time respiratory monitoring captures vast amounts of data, so cloud connectivity for doctors and patients is crucial. Galen Data’s scalable cloud platform can host Altair’s proprietary algorithms and AI features as well as offering all the necessary FDA, HIPAA, and ISO 13485:2016 compliance.

Altair’s CEO, Dr. Bruce Henderson, said “As we embark on performance and clinical testing prior to regulatory submission, integrating with Galen Data at this stage is allowing us to easily manage sensor data far earlier than we would otherwise have anticipated. The benefit is enormous, and the team at Galen could not have been more helpful.”

Now, with the strong foundation of the Galen Cloud, Altair’s developers can focus entirely on building their service without worrying about the infrastructure.

  • Altair medical achieves FDA breakthrough status
    Previous PostAltair medical achieves FDA breakthrough status
  • Next PostStorm ID, Altair Medical & NHS GGC develop a respiratory monitoring service for COVID-19 patients in new clinical trial
    Altair medical achieves FDA breakthrough status

Related Posts

PneumoWave raises £7.5 million Series A to accelerate clinical validation and regulatory submission of respiratory change diagnosis and monitoring platform
Press Release

PneumoWave raises £7.5 million Series A to accelerate clinical validation and regulatory submission of respiratory change diagnosis and monitoring platform

PneumoWave Featured in the Scotsman
Press Release

PneumoWave Featured in the Scotsman

Dr Gary Cooney appointed as Mental Health Lead
Press Release

Dr Gary Cooney appointed as Mental Health Lead

Dundee University start RESCU trial of PneumoWave’s wearable biosensor device aiming to cut opioid overdose deaths
Press Release

Dundee University start RESCU trial of PneumoWave’s wearable biosensor device aiming to cut opioid overdose deaths

pneumowave logo colour

About PneumoWave

Contact

Privacy Policy

PneumoWave’s technology is currently undergoing development and evaluation in clinical trials. Performance characteristics have yet to be established.

Website by genapse